Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Sakshi Jasra; Mohammed Kazemi; Nishi Shah; Jiahao Chen; Karen Fehn; Yanhua Wang; Ioannis Mantzaris; Noah Kornblum; Alejandro Sica; Liza Marie Bachier; Mendel Goldfinger; Kira Gritsman; Ira Braunschweig; Ulrich Steidl; Aditi Shastri; Amit Verma

doi:10.1186/s40164-020-00186-y

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Sakshi Jasra
, Mohammed Kazemi
, Nishi Shah
, Jiahao Chen
, Karen Fehn
, Yanhua Wang
, Ioannis Mantzaris
, Noah Kornblum
, Alejandro Sica
, Liza Marie Bachier
, Mendel Goldfinger
, Kira Gritsman
, Ira Braunschweig
, Ulrich Steidl
, Aditi Shastri
, Amit Verma

Research output: Contribution to journal › Letter › peer-review

8 Scopus citations

Abstract

Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

Original language	English (US)
Article number	1
Journal	Experimental Hematology and Oncology
Volume	10
Issue number	1
DOIs	https://doi.org/10.1186/s40164-020-00186-y
State	Published - Dec 2021

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1186/s40164-020-00186-y

Cite this

Jasra, S., Kazemi, M., Shah, N., Chen, J., Fehn, K., Wang, Y., Mantzaris, I., Kornblum, N., Sica, A., Bachier, L. M., Goldfinger, M., Gritsman, K., Braunschweig, I., Steidl, U., Shastri, A., & Verma, A. (2021). Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML. Experimental Hematology and Oncology, 10(1), Article 1. https://doi.org/10.1186/s40164-020-00186-y

Jasra, S, Kazemi, M, Shah, N, Chen, J, Fehn, K, Wang, Y , Mantzaris, I , Kornblum, N , Sica, A, Bachier, LM, Goldfinger, M , Gritsman, K, Braunschweig, I, Steidl, U , Shastri, A & Verma, A 2021, 'Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML', Experimental Hematology and Oncology, vol. 10, no. 1, 1. https://doi.org/10.1186/s40164-020-00186-y

@article{5488d354a3e34071904b98e1e26cac25,

title = "Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML",

abstract = "Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.",

author = "Sakshi Jasra and Mohammed Kazemi and Nishi Shah and Jiahao Chen and Karen Fehn and Yanhua Wang and Ioannis Mantzaris and Noah Kornblum and Alejandro Sica and Bachier, \{Liza Marie\} and Mendel Goldfinger and Kira Gritsman and Ira Braunschweig and Ulrich Steidl and Aditi Shastri and Amit Verma",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = dec,

doi = "10.1186/s40164-020-00186-y",

language = "English (US)",

volume = "10",

journal = "Experimental Hematology and Oncology",

issn = "2162-3619",

publisher = "BioMed Central",

number = "1",

}

TY - JOUR

T1 - Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

AU - Jasra, Sakshi

AU - Kazemi, Mohammed

AU - Shah, Nishi

AU - Chen, Jiahao

AU - Fehn, Karen

AU - Wang, Yanhua

AU - Mantzaris, Ioannis

AU - Kornblum, Noah

AU - Sica, Alejandro

AU - Bachier, Liza Marie

AU - Goldfinger, Mendel

AU - Gritsman, Kira

AU - Braunschweig, Ira

AU - Steidl, Ulrich

AU - Shastri, Aditi

AU - Verma, Amit

PY - 2021/12

Y1 - 2021/12

N2 - Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

AB - Optimal treatment of acute myeloid leukemia (AML) arising in elderly patients remains a challenge. FDA approval of Ivosidenib and Enasidenib, small molecule inhibitors of isocitrate dehydrogenase enzymes (IDH1 and 2) have opened new avenues of treatment. We present a 60-year-old woman with refractory AML, achieving complete response to the combination therapy of hypomethylating agent, Azacytidine with the IDH2 inhibitor, Enasidenib, and BCL2 inhibitor, Venetoclax. To our knowledge, this is the first case report of a patient with IDH2 mutated refractory AML achieving complete response to combination therapy with azacytidine, enasidenib and venetoclax.

UR - https://www.scopus.com/pages/publications/85098627998

UR - https://www.scopus.com/pages/publications/85098627998#tab=citedBy

U2 - 10.1186/s40164-020-00186-y

DO - 10.1186/s40164-020-00186-y

M3 - Letter

AN - SCOPUS:85098627998

SN - 2162-3619

VL - 10

JO - Experimental Hematology and Oncology

JF - Experimental Hematology and Oncology

IS - 1

M1 - 1

ER -

Case report of combination therapy with Azacytidine, Enasidenib and Venetoclax in primary refractory AML

Abstract

UN SDGs

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this